Hirobriz Breezhaler

Hirobriz Breezhaler is a prescription dry‑powder inhaler that contains the long‑acting β2‑adrenergic agonist indacaterol. It is marketed in the European Union for inhalation use and is designed to deliver a consistent dose of indacaterol to the lungs for bronchodilation in patients with chronic obstructive pulmonary disease.

Hirobriz Breezhaler is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It helps improve lung function and reduce symptoms such as breathlessness.

- Long‑term maintenance therapy for COPD - Reduces frequency of COPD exacerbations - Improves exercise tolerance in COPD patients - Used when a once‑daily bronchodilator is preferred - May be combined with other COPD maintenance medications as directed by a healthcare professional

Adverse reactions to Hirobriz Breezhaler are generally mild to moderate, but serious events can occur and require medical attention.

Common: - Headache - Throat irritation or discomfort - Cough after inhalation - Nasopharyngitis - Dry mouth - Tremor

Serious: - Paradoxical bronchospasm - Cardiovascular events such as tachycardia or arrhythmia - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Hypokalemia - Worsening of COPD symptoms

Before using Hirobriz Breezhaler, patients should be aware of several safety considerations.

- Assess for a history of cardiovascular disease or arrhythmias - Use caution in patients with severe hepatic impairment - Monitor blood potassium levels in patients at risk for hypokalemia - Evaluate for paradoxical bronchospasm after the first dose - Discuss pregnancy and breastfeeding status with a healthcare provider - Ensure proper inhaler technique to minimize local irritation

Hirobriz Breezhaler may interact with other medications, affecting safety or efficacy.

Avoid: - Non‑selective β‑blockers (e.g., propranolol) that can diminish bronchodilator effect - Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants that may increase cardiovascular risk

Use with caution: - Other β2‑agonists (short‑acting or long‑acting) due to additive tachycardia risk - Diuretics or corticosteroids that may predispose to hypokalemia - Anticholinergic agents, as combined bronchodilation may increase side‑effect profile - Theophylline, because of potential additive cardiac stimulation